Company / Net Income
SELLAS Life Sciences Group, Inc. Net Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$30.9M
FY2024
5-year range
-$37.3M / -$16.8M
FY2020-FY2024
Trend
+17.3%
vs FY2023
Sector context
#76 of 216
Health Care
What the data says
At -$31M, SELLAS Life Sciences Group, Inc.'s net income ranks #76 of 216 in the Health Care sector. Net Income returned to growth in FY2024 after 2 years of decline, reaching -$31M.
Based on SEC 10-K filings.
-$31M in FY2024.
Declined from -$21M to -$31M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#76 of 216 in Health CareTop 35% of 216This company -$30.9M Sector average $454.3M
▼
-106.8% below sector average
Key checks
Key Insights
- In FY2024, net income increased 17.3% year-over-year.
- Ranks #76 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2021.
- Lowest net income in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$30.9M | +17.3% |
| FY2023 | -$37.3M | -80.4% |
| FY2022 | -$20.7M | -23.5% |
| FY2021 | -$16.8M | +0.0% |
| FY2020 | -$16.8M | +13.1% |
| FY2019 | -$19.3M | +30.3% |
| FY2018 | -$27.7M | -16.5% |
| FY2017 | -$23.8M | -34.3% |
| FY2016 | -$17.7M | +72.3% |
| FY2015 | -$63.9M | -74.6% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026